Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
31
12
2020
accepted:
08
04
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
30
7
2021
Statut:
epublish
Résumé
Interleukin (IL)-19, a designated IL-20 subfamily cytokine, has been implicated in inflammatory disorders including rheumatoid arthritis, psoriasis and, lately, asthma. Here, through the analysis of transcriptomic datasets of lung tissue of large asthma cohorts, we report that IL-19 expression is upregulated in asthma and correlates with disease severity. The gene expression of IL-19 was significantly higher in lung tissue from patients with severe and mild/moderate asthma compared to healthy controls. IL-19 protein level, however, was significantly higher in the blood and saliva of patients with severe asthma compared to mild/moderate subgroups as measured by ELISA assay. IL-19 protein level was not affected by corticosteroid treatment in plasma. Our data provide insights into the potential use of IL-19 as a saliva marker for asthma severity and a potential therapeutic target.
Identifiants
pubmed: 34322544
doi: 10.1183/23120541.00984-2020
pii: 00984-2020
pmc: PMC8311130
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: F. Saheb Sharif-Askari has nothing to disclose. Conflict of interest: N. Saheb Sharif-Askari has nothing to disclose. Conflict of interest: S. Goel has nothing to disclose. Conflict of interest: B. Mahboub has nothing to disclose. Conflict of interest: A.W. Ansari has nothing to disclose. Conflict of interest: M-H. Temsah has nothing to disclose. Conflict of interest: A.M. Zakri has nothing to disclose. Conflict of interest: E. Ratemi has nothing to disclose. Conflict of interest: R. Hamoudi has nothing to disclose. Conflict of interest: Q. Hamid has nothing to disclose. Conflict of interest: R. Halwani has nothing to disclose.
Références
Lancet Respir Med. 2016 Jul;4(7):574-584
pubmed: 27283230
J Allergy Clin Immunol. 2009 May;123(5):1185-7
pubmed: 19361847
J Asthma. 2016 Oct;53(8):775-82
pubmed: 27050946
Pharmacogenomics J. 2013 Apr;13(2):121-9
pubmed: 22158329
Bioinformatics. 2004 Feb 12;20(3):307-15
pubmed: 14960456
Cell. 2001 Jan 12;104(1):9-19
pubmed: 11163236
Front Immunol. 2019 Apr 30;10:968
pubmed: 31114590
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12704-9
pubmed: 22802649
Br J Dermatol. 2005 Sep;153(3):591-5
pubmed: 16120148
Nat Rev Immunol. 2014 Dec;14(12):783-95
pubmed: 25421700
Annu Rev Immunol. 2011;29:71-109
pubmed: 21166540
J Immunol. 2001 Oct 1;167(7):3545-9
pubmed: 11564763
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Eur Respir J. 2016 Oct;48(4):1052-1062
pubmed: 27540019
Allergy. 2016 Dec;71(12):1684-1692
pubmed: 27225906
Exp Dermatol. 2006 Dec;15(12):991-1004
pubmed: 17083366
J Immunol. 2004 Dec 1;173(11):6712-8
pubmed: 15557163
Mucosal Immunol. 2014 Sep;7(5):1175-85
pubmed: 24518246
J Allergy Clin Immunol. 2008 Jun;121(6):1415-21, 1421.e1-3
pubmed: 18539194
J Allergy Clin Immunol. 2001 Nov;108(5):804-9
pubmed: 11692108
Rheumatology (Oxford). 2008 Jun;47(6):815-20
pubmed: 18397956
J Invest Dermatol. 2014 Nov;134(11):2757-2767
pubmed: 25046339
Nucleic Acids Res. 2015 Jul 13;43(12):e79
pubmed: 25829177
PLoS One. 2013 Oct 08;8(10):e76643
pubmed: 24116131